A drug manufacturer announced, on Thursday of their intention to buy the rights to develop and commercialise certain diabetes treatments in the Transition Therapeutics Incs pipeline.
Eli Lilly will pay an estimated $7 million for rights to gastrin-based therapies which treat diabetes patients. The gastrin hormone stimulates the production of gastric acid.
An unnamed Transition Therapeutics drugs, TT-223 is still being tested.
The agreement means that Lilly will pay $7m at first and possibly another $130m if the drugs get to the sales stage after being fully developed. Royalties will also be received by Transition Therapeutics based on the sales of gastrin therapies if successful.
The two companies are taking part in the planned midstage clinic trial of the TT-223 in type 2 diabetes further development will be the responsibility of Lilly.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…